N. N. Koberskaya

N. N. Koberskaya

Auto-generated profile, based on publicly available information

N. N. Koberskaya

Sechenov First Moscow State Medical University of the Ministry of Health of the Rusian Federation (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
EME. A. Mkhitaryan
E. A. Mkhitaryan
NVNatalya Vorobyeva
Natalya Vorobyeva
OTO. N. Tkacheva
O. N. Tkacheva
YKYu. V. Kotovskaya
Yu. V. Kotovskaya
NKN. N. Koberskaya
N. N. Koberskaya
LOL. N. Ovcharova
L. N. Ovcharova
Cognitive dysfunction is one of the most common disorders in the elderly and senile age. There are currently 57 million people with dementia worldwide.Objective: to assess cognitive functions, to understand the prevalence of cognitive impairment (CI) and to analyze their associations with socioeconomic, demographic and anthropometric factors and geriatric syndromes in people aged ≥65 years.Patients and methods. Subjects living in 11 regions of the Russian Federation took part in the EVKALIPT epidemiological study. The inclusion criterion was age ≥65 years. Participants were divided into three age groups (65–74 years, 75–84 years, and ≥85 years) according to the protocol. All patients underwent a comprehensive geriatric assessment, comprising a specially designed questionnaire and physical examination. Cognitive functions were assessed using the mini-Cog test. The study included 3545 patients (of which 30% were males) aged 65 to 107 years.Results and discussion. According to the data obtained in our study, CI was detected in 60.8% of the subjects, and severe disorders – in 19.9% (0 or 1 point according to the mini-Cog). Patients with CI had a lower socioeconomic status. One-way regression analysis showed that the risk of CI increased by 10% with increasing age for every 1 year but did not depend on the sex of the subjects. Associated with increased CI risk also were: living alone (by 28%), living in a nursing home (by 90%), widowhood (by 2.2 times) or absence of a partner (by 2.2 times), underweight (by 2.9 times) and normal body weight (by 1.6 times), disability (by 54%), primary (by 4.8 times) and secondary (by 75%) education, bad economic conditions (by 95%). On the contrary, the presence of overweight and obesity reduced the risk of CI by 14 and 24% respectively, living in a family – by 24%, having a spouse – by 55%, divorce – by 29%, having a job – by 73%, higher education and a scientific degree – by 55 and 59%, medium and good economic conditions – by 38 and 52%, respectively. In patients with CI, the incidence of all geriatric syndromes was higher.Conclusion. The frequency of CI among elderly patients was higher compared with data from other studies. The EVKALIPT study was the first to obtain national data on the prevalence and characteristics of CI in persons aged ≥65 years in the general population.

22 June 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
KSK. V. Shevtsova
K. V. Shevtsova
DRD. O. Rozhkov
D. O. Rozhkov
DGD. A. Grishina
D. A. Grishina
VGVladislav Griniuk
Vladislav Griniuk
VZV. V. Zakharov
V. V. Zakharov
VPV. A. Parfenov
V. A. Parfenov
Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD.

24 May 2022 in Russian Journal of Geriatric Medicine
Verified
Journal Article
Open access
PDF file
NKN. N. Koberskaya
N. N. Koberskaya
EME. A. Mkhitaryan
E. A. Mkhitaryan
ALA. B. Lokshina
A. B. Lokshina
DGD. A. Grishina
D. A. Grishina
Cognitive disorders are one of the most significant problems of older. Special attention should be paid to the diagnosis of early pre-dementia stages of cognitive impairment (CI): subjective, subtle and mild.The aim of this study was to determine the criteria of pre-mild: subjective and subtle cognitive decline (SCD).Material and methods. The study included 602 patients with pre-mild cognitive impairment with a mean age of 63.24±11.24 years and 515 patients with mild cognitive impairment aged 71.2±8.0 years. The indicators of patients were compared with those of 104 healthy people (average age 64.23±8.14 years) who did not complain of memory impairment and had no deviations during clinical and neuropsychological examination.Results and discussion. Groups of patients with subjective and subtle cognitive decline were distinguished, which differed in most characteristics. At the same time, in both groups of patients, deviations in the results of neuropsychological tests did not exceed one standard deviation from the average results for healthy people, which, in fact, allowed them to be attributed to «pre-mild» cognitive decline. The data obtained confirmed the heterogeneity of the «pre-mild» cognitive decline. The study also shows the allocation limitation of pre-mild cognitive impairment only on the basis of a formal approach based on the quantitative characteristics of neuropsychological research with a difference from control groups necessarily exceeding one standard deviation.Conclusion. The analysis showed the heterogeneity of pre-dementia and pre-mild cognitive impairments that are divided according to the degree of changes in objectively assessed cognitive functions with the similarity of subjective complaints. It is proposed to distinguish subjective cognitive decline with completely normal neuropsychological characteristics and subtle cognitive decline in the event of changes in individual indicators evaluating mainly the control functions and memory.

15 January 2020 in Russian neurological Journal
Verified
Journal Article
Closed access
NYN. N. Yakhno
N. N. Yakhno
NKN. N. Koberskaya
N. N. Koberskaya
VZV. V. Zakharov
V. V. Zakharov
DGD. A. Grishina
D. A. Grishina
ALA. B. Lokshina
A. B. Lokshina
ISI. Yu. Savushkina
I. Yu. Savushkina
Влияние возрастного фактора на «доумеренное» когнитивное снижение

29 May 2021 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
NKN. N. Koberskaya
N. N. Koberskaya
DGD. A. Grishina
D. A. Grishina
NYN. N. Yakhno
N. N. Yakhno
Recently, there is more and more evidence of the presence of a cognitive defect of varying severity in the clinical picture of ALS. A rare form of the disease is the amyotrophic lateral sclerosis (ALS) — dementia complex, characterized by a combination of dementia (usually frontotemporal) with ALS symptoms. The profile of cognitive deficit in ALS includes impairment of executive functions, memory, speech and visual-spatial disorders. A literature review on this problem is presented with a description of the clinical observation of ALS–dementia syndrome (frontal variant of possible Alzheimer’s disease). A patient with a reliable diagnosis of ALS showed rapidly progressive cognitive impairments in the form of hippocampal memory impairments, speech, visual-spatial impairments, and defective executive functions, accompanied by behavioral changes (apathy, decreased criticism). Magnetic resonance imaging of the brain revealed significant atrophy of the hippocampus, frontal lobe cortex, and left temporal lobe. In the literature, there are practically no descriptions of patients with a clinical picture of a combination of AD and ALS. Difficulties in diagnosing this condition are discussed. The relationship between these neurodegenerative diseases is discussed. The presented literature data and the presented clinical observation confi rm the expediency of studying cognitive functions in patients with suspected or signifi cant ALS, on the one hand, and analysis of the state of the central and peripheral neurons in patients with neuropsychiatric disorders of the frontotemporal type, on the other hand, which can be useful for diagnostics and treatment and rehabilitation measures.

10 March 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
NKN. N. Koberskaya
N. N. Koberskaya
Cardiovascular risk factors for the development of cognitive impairment and Alzheimer’s disease are ranked among the most significant ones, especially in elderly patients. The review provides data on the influence of such factors as arterial hypertension, arterial hypotension, heart failure, coronary heart disease, etc. on the development of cognitive deficiency. The presence of two or more of these risk factors generally tends to increase the possibility of the development of Alzheimer’s disease. The author examines the relationship between these factors and the development of Alzheimer’s disease. Insights into how CVD risk factors can cause progressive cognitive impairment provides further insight into the pathophysiology of Alzheimer’s disease and the identification of methods to prevent or treat CV risk factors for cognitive decline. The course and outcome of cardiovascular diseases depend on the patient’s age, previous medical history, lifestyle, primary prevention, genetic and pathological factors that affect structural and hemodynamic functions. The article addresses issues of therapy of these disorders. Methods of non-pharmacological therapy are discussed: the importance of the patient’s lifestyle, physical activity, nutritional issues, social activity of patients. Much attention is paid to the role of cognitive training in the management of patients with cognitive impairments. The correction of risk factors for stroke and the progression of chronic circulatory disorders is one of the most elaborated areas. The therapeutic potential drugs with a multifactorial mechanism of action are discussed. One of them is Ginkgo biloba extract EGb 761®, which meets the regulated content of active ingredients (flavone glycosides, terpene lactones and ginkgolic acid) and, perhaps, promises to be a more rational choice in the treatment of cognitive impairment. The role of Ginkgo biloba extract EGb 761® in the treatment of cardiovascular diseases is discussed.